A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia

NCT02672501 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia, B-Cell

Interventions

DRUG: anti-CD19-CAR-T cells

Sponsor

Shanghai GeneChem Co., Ltd.